SUPN 240517 26.00C (SUPN240517C26000) Stock Options, News & Quotes

US OptionsDetailed Quotes

SUPN240517C26000

Watchlist

3.10
0.000.00%

15min DelayClose May 17 13:41 ET

3.10High3.10Low

Intraday

News

Supernus Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Strategic Shifts and Pipeline ...
Yahoo FinanceMay 10 13:38 ET
Supernus Pharmaceuticals First Quarter 2024 Earnings: EPS: US$0.002 (Vs US$0.31 in 1Q 2023)
Yahoo FinanceMay 10 07:03 ET
Supernus Pharmaceuticals to Host Webcast to Review Interim Data From Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system
GlobeNewswireMay 9 16:05 ET
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q1 2024 Earnings Call Transcript
Yahoo FinanceMay 9 11:56 ET
Piper Sandler Remains a Buy on Supernus Pharmaceuticals (SUPN)
TipRanksMay 9 06:54 ET
Express News | Supernus Pharmaceuticals Reiterates FY24 Revenue $580M-$620M Vs $601.461M Est
BenzingaMay 8 17:25 ET

Comments

Meltyy

Apr 9 23:48

FDA PDUFA Update…

🗓️ Last week’s PDUFAs:
$Supernus Pharmaceuticals(SUPN.US)$ : CRL 4/8/24 🙁
⇒ SPN-830
⇒ OFF episodes in PD
⇒ NDA
⇒ PDUFA: 4/5/24
$Legend Biotech(LEGN.US)$ & $Johnson & Johnson(JNJ.US)$ : Approved 🎉
⇒ CARVYKTI (cilta-cel)
⇒ Multiple myeloma
⇒ sBLA
⇒ PDUFA: 4/5/24
$AstraZeneca(AZN.US)$ : Approved 🎉
⇒ Enhertu
⇒ HER2+ solid tumors
⇒ sBLA
⇒ PDUFA: Q2 2024
$2seventy bio(TSVT.US)$ & $Bristol-Myers Squibb(BMY.US)$ : Approved 🎉
⇒ Abecma
⇒ Multiple myeloma
⇒ sBLA
⇒ Delayed PDUFA
$Vanda Pharmaceuticals(VNDA.US)$...

rocketeer

Apr 5 14:53

$Supernus Pharmaceuticals(SUPN.US)$ so many insider selling non stop. hmmm

Lilo und Stitch

Apr 4 22:37

$Supernus Pharmaceuticals(SUPN.US)$
waiting patiently for fda 😌🙏

Meltyy

Apr 2 10:41

FDA PDUFA Update…

🗓️ Last week’s PDUFAs:
$Akebia Therapeutics(AKBA.US)$ : Approved 🎉
⇒ Vafseo (Vadadustat)
⇒ Anemia due to CKD
⇒ NDA
⇒ PDUFA: 3/27/24
$Merck & Co(MRK.US)$ : Approved 🎉
⇒ WINREVAIR (sotatercept)
⇒ Pulmonary arterial hypertension
⇒ BLA
⇒ PDUFA: 3/26/24
$AstraZeneca(AZN.US)$ : Approved 🎉
⇒ Ultomiris (ravulizumab)
⇒ NMOSD
⇒ sBLA
$Regeneron Pharmaceuticals(REGN.US)$ : CRL 🙁
⇒ Odronextamab
⇒ r/r FL and r/r DLBCL
⇒ BLA
⇒ PDUFA: 3/31/24
📌 This week’s PDUFAs: 🚨
$AstraZeneca(AZN.US)$ : 🤔
⇒...

The FDA PDUFA Calendar is a chronological calendar of PDUFA target dates as well as Advisory meetings (ADCOMM). PDUFA target dates are dates by which the FDA aims to deliver their decision regarding an NDA or BLA filing. These decisions can however come before the PDUFA target date.
$Vanda Pharmaceuticals(VNDA.US)$ $Legend Biotech(LEGN.US)$ $Supernus Pharmaceuticals(SUPN.US)$ $ImmunityBio(IBRX.US)$ $Aquestive Therapeutics(AQST.US)$ $X4 Pharmaceuticals(XFOR.US)$ $Liquidia(LQDA.US)$ $Neurocrine Biosciences(NBIX.US)$ $Moderna(MRNA.US)$ $Day One Biopharmaceuticals(DAWN.US)$
...